切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2020, Vol. 14 ›› Issue (02) : 103 -106. doi: 10.3877/cma.j.issn.1674-0793.2020.02.006

所属专题: 文献

论著

XPD 751基因单核苷酸多态性与结肠癌术后mFOLFOX6化疗疗效及预后的关系
乔青1,(), 刘娟1, 王爱鑫1, 余丹绯1, 苟福胜1, 林志宇1, 冷政伟2   
  1. 1. 614000 乐山市人民医院肿瘤科
    2. 637099 南充,川北医学院附属医院普外科
  • 收稿日期:2019-02-20 出版日期:2020-04-01
  • 通信作者: 乔青
  • 基金资助:
    四川省科研课题项目(16PJ133)

Relationship between XPD 751 single nucleotide polymorphism and mFOLFOX6 chemotherapy efficacy and prognosis after colon cancer surgery

Qing Qiao1,(), Juan Liu1, Aixin Wang1, Danfei Yu1, Fusheng Gou1, Zhiyu Lin1, Zhengwei Leng2   

  1. 1. Department of Oncology, People’s Hospital of Leshan City, Leshan 614000, China
    2. Department of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong 637099, China
  • Received:2019-02-20 Published:2020-04-01
  • Corresponding author: Qing Qiao
  • About author:
    Corresponding author: Qiao Qing, Email:
引用本文:

乔青, 刘娟, 王爱鑫, 余丹绯, 苟福胜, 林志宇, 冷政伟. XPD 751基因单核苷酸多态性与结肠癌术后mFOLFOX6化疗疗效及预后的关系[J/OL]. 中华普通外科学文献(电子版), 2020, 14(02): 103-106.

Qing Qiao, Juan Liu, Aixin Wang, Danfei Yu, Fusheng Gou, Zhiyu Lin, Zhengwei Leng. Relationship between XPD 751 single nucleotide polymorphism and mFOLFOX6 chemotherapy efficacy and prognosis after colon cancer surgery[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(02): 103-106.

目的

探讨DNA修复基因XPD 751位点单核苷酸多态性与结肠癌术后mFOLFOX6化疗疗效及预后的关系。

方法

前瞻性选择2013年6月至2015年6月乐山市人民医院接受根治性手术的105例结肠癌患者作为结肠癌组,另选择同期100名健康者作为对照组。DNA测序技术检测XPD 751位点单核苷酸多态性以及基因型频率,mFOLFOX6方案化疗6个月后对患者进行疗效评价,Kaplan-Meier法和Cox多因素回归分析XPD 751位点基因位点多态性与预后的关系。

结果

结肠癌组中XPD 751 AA基因型患者的疾病控制率(DCR)为86.44%(51/59),显著高于CA/CC基因型的65.22%(30/46)(χ2=6.603,P<0.05)。105例患者3年总生存率、无病生存率分别为69.52%、29.52%,其中AA基因型分别为77.97%、47.46%,高于CA/CC基因型的58.70%、6.52%,差异有统计学意义(χ2=4.712、20.817,P=0.030、<0.01),复发转移患者的AA基因型分布频率明显低于CA/CC基因型(30.51% vs 52.17%,χ2=5.055,P=0.025)。TNM分期和XPD 751 CA/CC基因型是影响结肠癌患者总体生存情况的危险因素(P=0.008、0.017)。

结论

XPD 751位点CA/CC基因型结肠癌患者根治性术后mFOLFOX6化疗的敏感性差,无病生存率和总生存率较低,检测XPD 751位点基因多态性有助于评估结肠癌患者化疗疗效和预后。

Objective

To investigate the relationship between single nucleotide polymorphism of DNA repair gene XPD 751 and the efficacy and prognosis of mFOLFOX6 chemotherapy after colon cancer surgery.

Methods

From June 2013 to June 2015, one hundred and five patients with colon cancer who underwent radical operation in People’s Hospital of Leshan City were prospectively selected as colon cancer group and 100 healthy persons as control group. Single nucleotide polymorphism and genotype distribution at XPD 751 locus was detected by DNA sequencing. The efficacy was evaluated at 6 months after mFOLFOX6 chemotherapy. Kaplan-Meier method and multivariate Cox regression were used to analyze the relationship between the polymorphism of the XPD 751 locus and the prognosis of patients.

Results

The disease control rate (DCR) of patients with XPD 751 AA genotype in colon cancer group was 86.44% (51/59), significantly higher than 65.22% (30/46) of CA/CC genotype (χ2=6.603, P<0.05). The 3-year overall survival rate and disease-free survival rate of the 105 patients were 69.52% and 29.52% respectively, and the AA genotype were 77.97% and 47.46%, higher than 58.70% and 6.52% of CA/CC genotype (χ2=4.712, 20.817, P=0.030, <0.01). The frequency of recurrence and metastasis in patients with AA genotype was significantly lower than that with CA/CC genotype (30.51% vs 52.17%, χ2=5.055, P=0.025). TNM staging and XPD 751 CA/CC genotype were risk factors for overall survival in patients with colon cancer (P=0.008, 0.017).

Conclusions

Colon cancer patients with XPD 751 CA/CC genotype show poor sensitivity to mFOLFOX6 chemotherapy, low disease-free survival rate and overall survival rate after radical operation. Detection of XPD 751 gene polymorphism is helpful to evaluate the efficacy and prognosis of chemotherapy in patients with colon cancer.

表1 结肠癌患者和健康者XPD基因751位点基因型频率[例(%)]
表2 结肠癌组XPD基因751位点不同基因型患者临床特征比较(例)
图1 AA基因型和CA/CC基因型结肠癌患者的生存曲线
表3 影响结肠癌患者预后的多因素分析
[1]
罗芳,石君. 术后辅助化疗联合免疫治疗对结肠癌患者外周血T淋巴细胞亚群数量的影响[J]. 临床合理用药杂志, 2015, 8(6): 111-112.
[2]
Kosugi C, Koda K, Ishibashi K, et al. Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage Ⅲ colon cancer: phase Ⅱ clinical study (The FACOS study)[J]. Int J Colorectal Dis, 2018, 33(6): 809-817.
[3]
Zheng DL, Tang GD, Chen YN, et al. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer[J]. Genet Mol Res, 2016, 15(2): 1-6.
[4]
陆俊国,李桃,徐燕飞, 等. ERCC2、RAD51和BAG-1基因多态性与晚期非小细胞肺癌铂类化疗敏感性的研究[J]. 现代肿瘤医学, 2015, 23(2): 203-205.
[5]
陈健,朱卫华,施民新, 等. ERCC2/XPD和XRCC1基因多态性与食管癌铂类药物化疗敏感性的关系[J]. 现代肿瘤医学, 2015, 23(20): 2936-2939.
[6]
Mehrzad J, Hashemi M, Jamshidi M, et al. Decreased expression of DNA repair genes (XRCC1 and XPD/ERCC2) in colorectal cancer in Iranian patients[J]. Int J Biol Sci, 2014, 10(2): 197-205.
[7]
滕雪,关尚为,刘朦朦, 等. 晚期非小细胞肺癌患者XPD基因多态性与铂类药物化疗临床疗效相关性的Meta分析[J]. 中国药房, 2016, 27(24): 3380-3384.
[8]
刘中华,陆海林. 着色性干皮病基因D单核苷酸多态性与铂类药物化疗后肾功能损伤的相关性[J]. 江苏医药, 2017, 43(19): 1422-1423.
[9]
Pearlman R, Frankel WL, Swanson B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer[J]. JAMA Oncol, 2017, 3(4): 464-471.
[10]
刘尚辉,范婷,肖莎, 等. 草酸铂治疗进展期结直肠癌疗效与ERCC1、ERCC2/XPD基因多态关联的Meta分析[J]. 中国现代医学杂志, 2015, 25(3): 1-6.
[11]
Khosa T, Aslam S, Mustafa S, et al. Association of single nucleotide polymorphisms in XRCC(194) and XPD(751) with age-related cataract[J]. Intel Ophthalmol, 2018, 38(3): 1135-1146.
[12]
陈雅敏,刘基巍,张昉. 结直肠癌基因XPD751和XPD312单核苷酸多态性与FOLFOX方案疗效相关性分析[J]. 中华肿瘤防治杂志, 2014, 21(24): 1946-1951.
[13]
Qian YY, Liu XY, Pei D, et al. The XPD Lys751Gln polymorphism has predictive value in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A systemic review and Meta-analysis[J]. Asian Pac J Cancer Prev, 2014, 15(22): 9699-9706.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 黄鸿初, 黄美容, 温丽红. 血液系统恶性肿瘤患者化疗后粒细胞缺乏感染的危险因素和风险预测模型[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 285-292.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[6] 崔宏帅, 冯丽明, 东维玲, 韩博. 腹腔镜右半结肠癌D3根治术+IGLN清扫术治疗局部进展期结肠肝曲癌的临床效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 566-569.
[7] 薛庆, 施赛叶, 徐雅文, 盛夏, 张芹芹. 追踪方法学联合失效模式与效应分析在膀胱灌注化疗患者中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 553-559.
[8] 宋小飞, 巫嘉文, 孙阳. 输尿管开口周围膀胱黏膜预离断联合早期膀胱灌注化疗在上尿路尿路上皮癌根治术中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 479-484.
[9] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[10] 关国欣, 罗福文. 结肠癌合并急性梗阻的个性化处理[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 459-463.
[11] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[12] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[13] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[14] 张颖, 赵鑫, 陈佳梅, 李雁. 术前化疗对CRS+HIPEC 治疗腹膜假黏液瘤预后影响的meta 分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 826-835.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要